Tissue | Expression Dynamics | Abbreviation |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00062604 | Esophagus | ESCC | DNA replication | 181/8552 | 260/18723 | 3.55e-15 | 2.05e-13 | 181 |
GO:00062754 | Esophagus | ESCC | regulation of DNA replication | 73/8552 | 107/18723 | 1.97e-06 | 2.28e-05 | 73 |
GO:00063602 | Esophagus | ESCC | transcription by RNA polymerase I | 42/8552 | 55/18723 | 3.41e-06 | 3.78e-05 | 42 |
GO:00063532 | Esophagus | ESCC | DNA-templated transcription, termination | 15/8552 | 21/18723 | 1.54e-02 | 4.96e-02 | 15 |
GO:00062603 | Oral cavity | OSCC | DNA replication | 159/7305 | 260/18723 | 3.25e-13 | 1.59e-11 | 159 |
GO:00062753 | Oral cavity | OSCC | regulation of DNA replication | 62/7305 | 107/18723 | 5.49e-05 | 4.54e-04 | 62 |
GO:00063601 | Oral cavity | OSCC | transcription by RNA polymerase I | 36/7305 | 55/18723 | 6.42e-05 | 5.22e-04 | 36 |
GO:000626012 | Skin | cSCC | DNA replication | 106/4864 | 260/18723 | 1.18e-07 | 2.77e-06 | 106 |
GO:00063603 | Skin | cSCC | transcription by RNA polymerase I | 30/4864 | 55/18723 | 6.13e-06 | 8.70e-05 | 30 |
GO:00062755 | Skin | cSCC | regulation of DNA replication | 44/4864 | 107/18723 | 4.41e-04 | 3.39e-03 | 44 |
GO:00063533 | Skin | cSCC | DNA-templated transcription, termination | 12/4864 | 21/18723 | 2.40e-03 | 1.38e-02 | 12 |
GO:00062606 | Thyroid | PTC | DNA replication | 114/5968 | 260/18723 | 3.09e-05 | 2.95e-04 | 114 |
GO:00063604 | Thyroid | PTC | transcription by RNA polymerase I | 28/5968 | 55/18723 | 2.55e-03 | 1.31e-02 | 28 |
GO:000626013 | Thyroid | ATC | DNA replication | 124/6293 | 260/18723 | 1.58e-06 | 1.93e-05 | 124 |
GO:00062756 | Thyroid | ATC | regulation of DNA replication | 50/6293 | 107/18723 | 3.25e-03 | 1.46e-02 | 50 |
GO:000636011 | Thyroid | ATC | transcription by RNA polymerase I | 28/6293 | 55/18723 | 5.94e-03 | 2.39e-02 | 28 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TTF1 | SNV | Missense_Mutation | | c.1258N>C | p.Asp420His | p.D420H | Q15361 | protein_coding | deleterious(0.04) | benign(0.046) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
TTF1 | SNV | Missense_Mutation | novel | c.627N>C | p.Glu209Asp | p.E209D | Q15361 | protein_coding | tolerated(0.1) | benign(0.031) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD |
TTF1 | SNV | Missense_Mutation | rs763134689 | c.1279N>A | p.Ala427Thr | p.A427T | Q15361 | protein_coding | tolerated(1) | benign(0) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
TTF1 | SNV | Missense_Mutation | | c.2064G>T | p.Lys688Asn | p.K688N | Q15361 | protein_coding | deleterious(0) | possibly_damaging(0.838) | TCGA-Q1-A73O-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
TTF1 | SNV | Missense_Mutation | novel | c.731N>T | p.Arg244Ile | p.R244I | Q15361 | protein_coding | tolerated_low_confidence(0.15) | benign(0) | TCGA-VS-A8EL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
TTF1 | SNV | Missense_Mutation | | c.2647G>T | p.Gly883Cys | p.G883C | Q15361 | protein_coding | deleterious_low_confidence(0.03) | possibly_damaging(0.809) | TCGA-A6-2686-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
TTF1 | SNV | Missense_Mutation | rs200157893 | c.1313G>A | p.Arg438Gln | p.R438Q | Q15361 | protein_coding | tolerated(0.71) | benign(0) | TCGA-A6-2686-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
TTF1 | SNV | Missense_Mutation | | c.914N>T | p.Ala305Val | p.A305V | Q15361 | protein_coding | tolerated_low_confidence(0.18) | benign(0) | TCGA-A6-5661-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
TTF1 | SNV | Missense_Mutation | rs199931383 | c.1996N>T | p.Arg666Cys | p.R666C | Q15361 | protein_coding | deleterious(0.01) | probably_damaging(0.971) | TCGA-A6-6141-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | 5-fu | SD |
TTF1 | SNV | Missense_Mutation | | c.1158N>T | p.Lys386Asn | p.K386N | Q15361 | protein_coding | deleterious(0) | benign(0.18) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |